Trial Profile
Pilot Study of the ReZolve Sirolimus-Eluting Bioresorbable Coronary Stent
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease
- Focus Therapeutic Use
- Acronyms RESTORE
- Sponsors REVA Medical
- 27 Mar 2023 Status changed from active, no longer recruiting to completed.
- 12 Sep 2018 Planned End Date changed from 1 Oct 2018 to 1 Apr 2019.
- 26 Apr 2017 Planned End Date changed from 1 Sep 2018 to 1 Oct 2018.